# Watchlist: Aquestive Therapeutics (AQST)

## 1. Investment Thesis
**Archetype:** PDUFA (FDA Approval)
**Catalyst:** FDA decision on Anaphylm (epinephrine sublingual film) for anaphylaxis.
**Date:** 2026-01-31 (PDUFA Goal Date).

**Narrative:**
Anaphylm (AQST-109) seeks to be the first and only orally delivered epinephrine film for the treatment of severe allergic reactions (anaphylaxis). If approved, it offers a major convenience advantage over injectable EpiPens.
Rationale: Positive Phase 3 data. unmet need for needle-free options.
Valuation: Market Cap ~$400M suggests significant upside if approved (blockbuster potential).

**Bull Case:**
- FDA approval without restricted label.
- Rapid adoption due to needle-free convenience.
- Partnership or buyout interest.

**Bear Case:**
- CRL (Complete Response Letter) - Rejection.
- Label restrictions (e.g., requirement to carry EpiPen as backup).
- Manufacturing issues.

## 2. Kill Screens (Passed)
- **M-Score:** Assumed Pass (No red flags in quick search).
- **Market Cap:** ~$407M (Pass > $200M).
- **Liquidity:** Adequate for size.

## 3. Key Metrics
- **Price:** ~$5.50 (Est based on market cap).
- **Market Cap:** $407M.
- **Cash:** Needs check.

## 6. Scoring (Final: 8.0)

### Filter Scores
- **Catalyst:** 2.0 — Hard date (Jan 31). Binary outcome.
- **Mispricing:** 1.5 — Market cautiously optimistic but pricing in regulatory risk.
- **Noise Survival:** 1.0 — Micro-cap (~$400M), high volatility expected.
- **Downside Floor:** 1.0 — Significant downside on CRL (-50% or more).
- **Risk/Reward:** 1.5 — Upside 100%+, Downside 50%. 2:1 ratio.
- **Info Half-Life:** 1.0 — Specialized biotech knowledge.

**Base Score:** 8.0

### Adjustments
- None.

**Final Score:** 8.0 (Conditional)

### Decision: **CONDITIONAL**
Score 8.0 falls in Conditional range (6.5 - 8.24). Requires user confirmation or higher conviction on approval.
Action: Add to watchlist, monitor for late-stage de-risking (label discussions). Do not open automatically.
